New hope for aggressive breast cancer: adding immunotherapy to standard treatment
NCT ID NCT03515798
Summary
This study is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy before surgery helps eliminate aggressive inflammatory breast cancer tumors. It involves 52 adults with a specific type of breast cancer (HER2-negative) that has not spread. The main goals are to see if this combination completely removes the cancer at surgery and to monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CENTRE Francois Baclesse
Caen, France
-
Centre Georges Francois Leclerc
Dijon, 21079, France
-
Centre Henri Becquerel
Rouen, France
-
Centre Leon Berard
Lyon, France
-
Centre Paul Strauss
Strasbourg, France
-
Clinique de L'Europe
Amiens, France
-
IUCT-Oncopole Institut Claudius Rigaud
Toulouse, France
-
Institut BERGONIE
Bordeaux, France
-
Institut Curie
Paris, France
-
Institut Curie hopital rene huguenin
Saint-Cloud, France
-
Institut Sainte Catherine
Avignon, France
-
Institut de cancérologie de la loire
Saint-Priest-en-Jarez, France
Conditions
Explore the condition pages connected to this study.